# Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma

> **NCT05483257** · — · COMPLETED · sponsor: **BAIYONG SHEN** · enrollment: 226 (actual)

## Conditions studied

- Pancreatic Cancer Resectable

## Interventions

- **DEVICE:** Multigene panel for next-generation sequencing

## Key facts

- **NCT ID:** NCT05483257
- **Lead sponsor:** BAIYONG SHEN
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-14
- **Primary completion:** 2020-08-03
- **Final completion:** 2021-09-13
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2022-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05483257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05483257, "Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05483257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*